New Diarrhea Vaccine Shows Promise in Human Trials

After more than 20 years of work, Canadian researchers have moved one giant step closer to preventing a bacterial disease that kills thousands and sickens millions around the world every year.

Scientists at the University of Guelph just completed a successful human trial of the first vaccine for Campylobacter jejuni, a bacteria commonly found in undercooked chicken that causes severe diarrhea, fever, and cramps. In developing countries, the infection can be fatal, especially for children and people with weakened immune systems.

Dr. Mario Monteiro and his team tested their sugar-based vaccine on about 60 healthy adults between 2022 and 2024 at Cincinnati Children's Hospital. The results exceeded expectations: the vaccine proved safe, with only minor side effects like muscle soreness at the injection site.

The most exciting finding came as a surprise. The strongest immune response happened at the lowest vaccine dose, which means future versions could protect against multiple strains of the bacteria at once.

Campylobacter affects millions globally, causing one of the most common types of bacterial diarrhea worldwide. Last year alone, an outbreak in India killed 11 people through contaminated water. Travelers of any age face risk when visiting areas where the infection is common.

The bacteria also triggers Guillain-Barré syndrome in some patients, a severe autoimmune disorder that attacks the nervous system. The vaccine could prevent both the initial infection and this dangerous complication.

The Ripple Effect

This breakthrough matters beyond individual health. The World Health Organization has recognized antibiotic-resistant bacteria as a "hidden pandemic" that threatens modern medicine. Vaccines like this one offer protection without relying on antibiotics, helping preserve these life-saving drugs for when they're truly needed.

Monteiro's lab is unique worldwide for developing vaccines based on bacterial sugars rather than proteins. While this approach involves complex chemistry and takes longer to develop, it can be more effective for sugar-rich bacteria like Campylobacter.

The vaccine also represents successful international collaboration. The U.S. National Institutes of Health funded the trial, while the Naval Medical Research Center tested vaccines created at the Canadian university.

An earlier trial in 2014 showed promise but didn't trigger strong enough immune responses. This time, Monteiro's team identified that a key sugar molecule was missing from the first version. Adding it back made all the difference.

The next step is a Phase 2 trial with hundreds more volunteers to confirm the vaccine actually prevents illness, not just triggers immune responses. If successful, the vaccine could reach pharmacy shelves within years.

"Commercialization of science is on everyone's minds these days, but the marketability is not our main motivation," Monteiro says. "When it reaches the clinical shelves, it could save a lot of lives."